February 6, 2018 – Varian announced it has acquired privately-held Mobius Medical Systems, a radiation oncology Quality Assurance (QA) software company. This acquisition expands Varian's work in radiation medicine by increasing its portfolio of patient treatment plan QA and machine QA technologies and enables the company to potentially impact more patients around the globe with software solutions designed to assure the quality of treatments.
The acquisition of Mobius is consistent with Varian's long-term growth and value creation strategy and broadens its cancer care portfolio. The integration of additional QA tools into the Varian ecosystem will allow advanced QA processes to be more seamlessly combined into treatment workflows. Additionally, Varian also can ensure that QA methods advance at the same time as Varian introduces new treatment techniques.
“Varian places high value on the market-leading Mobius QA products, including Mobius3D and DoseLab, and is dedicated to expanding their global reach,” said Kolleen Kennedy, president of Varian's Oncology Systems business. “The two companies have similar cultures with deep commitments to enabling quality cancer care for patients around the globe."
The Mobius QA software is in use at over 1000 sites worldwide to ensure patients receive high-quality care. Mobius3D is a 3-D dose verification and IMRT/VMAT treatment delivery QA system. Mobius3D performs 3-D dose verification for patient plans, supports verification checks throughout the entire clinical process for IMRT and VMAT, and includes modular staged testing to reinforce the confidence of the medical physicist in the patient plan and treatment delivery. DoseLab is fast, simple and powerful software for quality assurance of medical linear accelerators.
For more information: www.varian.com/mobius
April 18, 2024 
